Skip to Main Content

Paper Details

Early antibody treatment, inflammation, and risk of post-COVID conditions.
mBio
6
2023
CCP, COVID conditions, COVID-19, IL-6, PCC, PCCs, Post-COVID conditions, SARS-CoV, SARS-CoV-2, SARS-CoV-2 infection, anosmia, control plasma, diabetes mellitus, fatigue, inflammation, obesity, participants, post-
Author NameAffiliation
Kelly A GeboJohns Hopkins University School of Medicine
Shmuel ShohamJohns Hopkins University School of Medicine
Judith S CurrierUniversity of California los angeles
Judith S CurrierUniversity of California los angeles
Janis E BlairMayo Clinic Hospital
Andrew PekoszJohns Hopkins University Bloomberg School of Public Health
Evan M BlochJohns Hopkins University School of Medicine
Arturo CasadevallJohns Hopkins University Bloomberg School of Public Health
Arturo CasadevallJohns Hopkins University Bloomberg School of Public Health
Aaron A R TobianJohns Hopkins University School of Medicine
  • 1 - 10

Datasets

Release 1.2